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 Late SV40 Factor (LSF) is a ubiquitously expressed mammalian transcription 
factor and an oncogene in Hepatocellular Carcinoma (HCC), a deadly cancer that 
currently has poor treatment options. LSF is expressed at low levels in normal 
hepatocytes but is overexpressed in HCC making it a key target for treating HCC. Small 
molecule inhibitors called Factor Quinolinone Inhibitors (FQIs) that specifically target 
LSF have been developed as possible chemotherapeutics to treat HCC. FQI1, a lead 
inhibitor, reduces HCC tumor sizes in mouse models without any evident toxicity in other 
organs.   
 The focus of many recent studies regarding LSF has been to characterize it as an 
oncogene in HCC, however little is known about how it functions in normal hepatocytes. 
Understanding the role of LSF in hepatocytes could provide more insight into how it 
drives HCC as well as give more insight into how to target it in HCC. Here, FQI1 was 
used as a tool to uncover phenotypes in immortalized fetal hepatocytes (FH-B) that result 
from inhibiting the low levels of LSF expressed in this cell line. Rapid morphological 
phenotypes resulting from FQI1 treatment suggested a disruption in a non-transcriptional 
		 vi 
process, which was unexpected since LSF is a transcription factor. Further investigation 
revealed that LSF and a-tubulin interact in immortalized human fetal hepatocytes and 
that this interaction at least partially disrupted upon short treatment with FQI1 in FH-B 
cells. These findings suggest mechanisms for non-transcriptional roles that LSF may have 
in addition to its roles as a transcription factor. 
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CHAPTER 1: INTRODUCTION 
1.1 LSF and its Biological Roles 
 Late SV40 Factor (LSF), is a ubiquitously expressed mammalian protein  
(Swendeman et al., 1994) that belongs to the CP2 (CCAAT box-binding protein 2-a 
misnomer) division of the evolutionarily conserved grainyhead (GRH)/CP2 family of 
transcription factors (Traylor-Knowles et al., 2010; Venkatesan, et al., 2003). LSF was 
first identified as a transcription factor in HeLa cells where it was found to bind the 
promoter of the major late Simian Virus 40 promoter leading to transcriptional activation 
(Kim, et al., 1987). LSF binds DNA as a homotetramer but exists primarily as a dimer in 
solution (Shirra & Hansen, 1998). It is involved in many biological processes such as the 
cell cycle and DNA synthesis and has been linked to Alzheimer’s disease and cancer 
(Kotarba et al., 2018; Santhekadur et al., 2012; Veljkovic & Hansen, 2004). LSF 
regulates G1/S progression during the cell cycle via one of its major targets, the 
thymidylate synthase gene, encoding the essential G1-S enzyme thymidylate synthase 
which is required for DNA synthesis and cell survival (Powell et al., 2000). Studies have 
also revealed the role of LSF as an oncogene in hepatocellular carcinoma (HCC). LSF is 
overexpressed in many human HCC cell lines compared to normal hepatocytes and has 
been found to robustly upregulate genes associated with tumorigenesis, invasion, 
angiogenesis and chemoresistance such as SPP1 which encodes osteopontin, a protein 
crucial for metastasis and matrix metalloproteinase-9 (MMP-9), a tumor invasion factor 




1.2 LSF-Protein Interactions 
 As other transcription factors, LSF regulates transcription by forming complexes 
with other proteins in various contexts. LSF forms heterodimers with subfamily 
members, LBP-1a, LBP-9 and LBP-1b, which as a complex have been shown to bind 
DNA (Yoon et al., 1994). The interaction between LBP-1b and LSF has been 
demonstrated to be important for the nuclear localization of LSF (Sato et al., 2005). LSF 
regulates DNA methylation and the epigenome by forming complexes with DNMT1, the 
maintenance DNA methyltransferase, and accessory protein UHRF1 (Chin et al., 2016).  
Activation of the LSF driven thymidylate synthase gene is abolished by overexpression 
of Fe65, an adaptor protein primarily expressed in neuronal cells that forms complexes 
with LSF and inhibits LSFs ability to activate the thymidylate synthase gene promoter 
(Bruni et al., 2002; McLoughlin & Miller, 2008; Zambrano et al., 1998). YY1 is a 
ubiquitously expressed transcription factor that has been shown to interact with LSF to 
repress HIV LTR expression (Coull et al., 2000; Kang et al., 2005). Overexpression of 
LSF in pancreatic cancer has been linked to the beta-catenin/TCF pathway, critical for 
embryonic development and tumorigenesis through the regulation of various genes, via 
LSF’s interaction with beta-catenin that in turn strengthens the beta-catenin/TCF 
interaction and leads to activation of genes associated with tumorigenesis. (Yuedi et al., 
2017). YAP, a transcription co-factor associated with liver tumorigenesis, is activated by 
interacting with LSF that then enhances YAP’s interaction with other transcription 
factors and altogether leads to the formation of DNA-binding complexes that activate 
oncogenic genes (Zhang et al., 2017). 
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Recent studies have indicated that LSF-protein complexes are also involved in 
non-transcriptional processes. In HEK-293 cells, LSF directly interacts with both SET8, a 
protein primarily characterized as a histone H4 lysine 20-specific monomethyltransferase 
(Dillon et al., 2005),  and a-tubulin allowing SET8 to methylate lysine residues on a-
tubulin (Chin et al., manuscript submitted). 
1.3 LSF Specific Small Molecule Inhibitor: Factor Quinolinone Inhibitor (FQI) 
Factor quinolinone inhibitor 1 (FQI1) is the initial lead small molecule inhibitor 
that specifically targets and inhibits both LSF binding to DNA and certain LSF-protein 
interactions. LSF was screened against 110,000 commercially available compounds using 
a fluorescence polarization assay to evaluate the ability of each compound to diminish 
LSFs ability to bind DNA in vitro. Electrophoretic mobility shift assays (EMSA) were 
used as secondary screens to remove nonspecific inhibitors that target multiple DNA-
protein interactions. Compounds that only targeted LSF-DNA binding activity were 
identified whereas any compounds that also inhibited the DNA binding activity of the 
widely expressed transcription factors Sp1, Oct1 and E2F3, which represent a wide 
variety of DNA binding domain motifs, were eliminated. Through this initial screen, 4-
aryl-3,4-dihydroquinolin-2(1H)-ones were identified as specific and potent inhibitors of 
LSF-DNA binding in vitro. The compounds that were identified as LSF-DNA binding 
inhibitors in vitro were also studied in a cellular context using a LSF-dependent 
luciferase reporter assay. Some of the compounds also inhibited LSF transcriptional 
activity in this assay. The specificity of FQI1 to LSF was further verified by normalizing 
luciferase activity from the LSF-dependent reporter construct to a Herpes simplex viral 
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thymidine kinase (HSV-tk) promoter that drove a renilla luciferase gene and a USF-
dependent reporter construct that is activated by USF. The activity of both constructs was 
not affected by FQI1 suggesting that FQI1 did not affect the transcription factors that 
regulate the activity of these constructs.  The final stringent specificity test was a cellular 
assay for p53 transcriptional activity (Grant et al., 2012). At the time, the structure of 
LSF or any of its family members was unknown (Venkatesan et al., 2003). However, one 
study predicted a similarity in the structure of the DNA-binding region of LSF and the 
p53 family using protein-folding algorithms (Kokoszynska et al., 2008). p53 is 
responsible for the transcriptional activation of p21 and upon induction of p53 activity, 
treatment with FQI1 at levels that diminish LSF activity did not affect p21 expression 
(Grant et al., 2012). Finally, a recent study comparing phenotypic effects when QGY-
7703 cells, an aggressive HCC cell line, were treated with FQI1 versus when LSF was 
knocked down using LSF siRNA has shown that both led to similar effects on gene 
expression, specifically a reduction in RNA levels of mitotic regulators Aurora Kinase B 
and CDC20, and the same mitotic defects (Willoughby et al., unpublished manuscript). 
Altogether, these results support the notion that FQI1 is a highly specific inhibitor of 
LSF.    
1.4 FQIs as Chemotherapeutics 
The fact that LSF has oncogenic properties and is highly overexpressed in HCC 
compared to normal tissue led to studies to determine whether FQI1 could be used as a 
potential chemotherapeutic. In vitro, treating QGY-7703 cells and hepatoblastoma cell 
line, Hep-3B led to apoptosis via mitotic defects (Grant et al., 2012; Rajasekaran et al., 
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2015). In a subcutaneous xenograft mouse model with tumors derived from QGY-7703 
cells, treatment with FQI1 showed substantial decrease in tumor growth and volume 
while no evident toxicity was detected in other tissues such as the liver, stomach and 
intestine. In addition, the mice had normal body weight, growth and general behavior 
further indicating that there was no general toxicity caused by treatment with FQI1 
(Grant et al., 2012). Other studies in genetically modified mice that developed HCC 
showed that treating these mice with FQI1 led to a decrease in tumors in the liver while 
normal levels of liver-derived enzyme levels were detected in the blood indicating that 
the liver was evidently functioning normally with no obvious signs of toxicity 
(Rajasekaran et al., 2015). Altogether, these results suggested that the effects of FQIs 
may be limited to cancerous liver cells. 
1.5 Role of LSF in Normal Hepatocytes 
While LSF has been well characterized as an oncogene in HCC, not much is 
known about its role in normal hepatocytes. Initial studies in the Hansen Laboratory have 
shown that asynchronous immortalized human fetal hepatocytes (FH-B) (Wege et al., 
2003) that normally display an elongated shape, contract and display a rounded up shape 
after one hour of FQI treatment (Pietro Scribani Rossi, personal communications). 
Images acquired every 5 minutes post FQI1 treatment for 30 minutes showed the cells 
beginning to contract within 10 minutes and rapidly returning back to their normal 
morphology after FQI1 was washed off the cells. (Patrick Stoiber, personal 
communications). These results, taken together, strongly suggest a non-transcriptional 
effect perhaps related to the microtubule cytoskeleton.  
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Microtubules are essential for cell shape, cell motility, intracellular transport and 
are a target for many cancer therapeutics. They are highly dynamic structures that go 
through rapid cycles of polymerization and depolymerization both in vitro and in vivo. 
The functions and dynamics are regulated by post-translational modifications and the 
interaction of the microtubule subunits, a- and b- tubulins, with proteins classified as 
microtubule-associated proteins (MAPs) (Janke & Bulinski, 2011). A recent study 
showed that LSF directly interacts with a-tubulin in HEK-293 cells and enhances tubulin 
polymerization in vitro while FQI1 treatment lead to inhibition of the LSF-tubulin 
interaction and inhibition of tubulin polymerization respectively (Chin et al., manuscript 
submitted). It was hypothesized that the same LSF-a-tubulin interaction disrupted by 
FQI1 in HEK-293 cells is also disrupted by FQI1 in FH-B cells causing the microtubules 
to destabilize and thus disrupting the cytoskeleton, leading to the FH-B cells contracting 




CHAPTER 2: MATERIALS & METHODS 
2.1 Cell line/Cell Culture 
Human fetal hepatocytes stably expressing the catalytic subunit of telomerase, 
telomerase reverse transcriptase, were obtained from the Sanjeey Gupta Laboratory and 
are referred to as telomerase immortalized fetal hepatocytes (FH-B) (Wege et al., 2003). 
FH-B cells were cultured in media composed of Dulbecco’s modification of Eagle’s 
Medium with 4.5 g/L glucose, L-glutamine and sodium pyruvate (DMEM) (Corning 
Cellgro) supplemented with 10% fetal bovine serum (FBS) (Atlanta Biologicals) in an 
incubator with a 5% CO2 atmosphere at 37°C. Cells were passaged up to 8 times every 3 
days at 70-80% confluency.  
2.2 Cloning 
A previously cloned pBABE-puro-3XFLAGBioLSF-IRESEGFP vector 
containing a mutation that changed an arginine residue to a stop codon was used to 
design polymerase chain reaction (PCR) primers that corrected the mutation and 
contained BglII and SalI restriction enzyme recognition sites. The BioLSF insert was 
created by first amplifying by PCR the 3XFLAGBioLSF-IRESEGFP sequence from the 
vector containing the mutation using the primers described above and then digesting the 
amplified cDNA with the restriction enzymes BglII and SalI (New England BioLabs). A 
pBABE-puro vector (Addgene, #1764) was digested using the same restriction enzymes 
and the BioLSF insert was ligated into the linear pBABE-puro vector creating a pBABE-




2.3 Transfecting GP2-293 Cells for Retrovirus Production 
GP2-293 packaging cells (Clontech) were cultured in DMEM supplemented with 
10% FBS (media). 10 cm tissue culture plates were coated with 1% collagen (from rat 
tails; gift from Bradham Lab) overnight at 4°C. The following day, the collagen was 
removed and the plates were washed three times with DMEM and phosphate buffered 
saline (PBS) (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4•7H2O, 1.4 KH2PO4). GP2-
293 packaging cells (2x106) were seeded onto each collagen-coated plate. The following 
day, the cells were transfected using lipofectamine. 5.3 µg of pVSV-G plasmid 
(Clontech), 10.6 µg of pBABE-puro-3XFLAGBioLSF-IRESEGFP and 45 µL of 
lipofectamine (Invitrogen) were added to 3 mL of Opti-MEM (Gibco) and left to incubate 
at room temperature in a tissue culture hood for 25 minutes. The media on the cells was 
replaced with 7 mL of fresh media and 3 mL of the lipofectamine transfection reagent 
and incubated at 37°C, 5% CO2 for 5 hours. The media containing transfection reagent 
was removed and the cells were washed once with 1X PBS. The cells were then treated 
with 10% sterile glycerol in 10 mL DMEM and left to incubate at room temperature in 
the tissue culture hood for 1.5 minutes. The DMEM with glycerol was removed and the 
cells were washed with once with 1X PBS. Ten mL of fresh media was added to the cells 
and the plates were then incubated in a 5% CO2 atmosphere at 37°C for 2 days. 
2.4 Retroviral Infection of FH-B Cells 
Two days post transfection with the pBABE plasmid, the media on the transfected 
GP2-293 cells, now containing retrovirus, was transferred to a 50 mL conical tube. The 
media was filtered using a 45 µM syringe filter (Pall Corporation) to remove any GP2-
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293 cells and polybrene (to a final concentration of 8 µg/mL) was added to the filtered 
media. The retrovirus and polybrene containing media was then transferred to a T-75 
flask containing FH-B cells at 50% confluence and incubated in a 5% CO2 atmosphere at 
37°C for one day. The next day, the retrovirus and polybrene containing media was 
removed and replaced with 10 mL of fresh media. 
2.5 Fluorescence Activated Cell Sorting (FACS) 
EGFP+ cells (transduced) were sorted from EGFP- cells (non-transduced) using 
the Sony SH700S cell sorter. The cells were sorted using a 488 nm laser with a sample 
pressure of 7. FH-B parental cells were used as a negative control to set the background 
signal threshold. A total of 4,292 cells were collected during sort 1 and 238,974 cells 
were collected during sort 2. The cell line established from the EGFP+ cells were referred 
to as FH-B Biotinyl-Domain-LSF (FH-B BioLSF).   
2.6 Immunofluorescence 
Coverslips were placed in 35 mm plates and left in a closed tissue culture hood 
with the UV light on to sterilize for 30 minutes. FH B and FH-B BioLSF cells (2x105) 
were seeded onto each coverslip in the 35 mm plates and left in the 37°C, 5% CO2 
incubator overnight. The following day, the media was aspirated off and the cells were 
washed once with 1X PBS. Two mL of 10% formalin (Sigma-Aldrich) was added to each 
coverslip and incubated at room temperature in the tissue culture hood for 10 minutes to 
fix the cells. The formalin was removed and the cells were washed three times with 1X 
PBS. Two mL of 0.1% Triton-X-100 was added to each coverslip and the 35 mm plates 
were rotated on the Orbital Shaker at 50 rpm for 10 min at room temperature to 
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permeabilize the cell membranes. The Triton-X-100 was removed and cells were washed 
3 times in 1 mL of 1X PBS for 5 minutes each on the Orbital Shaker at 50 rpm. Two mL 
of 5% Bovine Serum Albumin (BSA) (Fisher BioReagents, BP1600-100) in PBST (1X 
PBS, 0.1% Tween20) was added to the coverslips and rotated on the Orbital Shaker at 50 
rpm for 1 hour at room temperature. Subsequently, 500 µL of α-FLAG primary antibody 
(see Table 2.1 for more information) in 500 µL of 5% BSA in PBST was added to each 
coverslip and rotated on the Reliable Scientific rotator overnight at 4°C. The following 
day, the primary antibody was removed and the coverslips were washed three times with 
2 mL of PBST on the Orbital Shaker at 50 rpm for 5 minutes at room temperature. One 
mL of Cy5-labeled goat α mouse antibody (1:1,000) (gift from Cooper Lab) in 5% BSA 
in PBST was added to each coverslip. The plates containing the coverslips were then 
covered and rotated on the Orbital Shaker at 50 rpm at room temperature for 1 hour. The 
secondary antibody was removed and 1 mL of Hoechst 33342, trihydrochloride, 
trihydrate (1:1,000, 1 µg/mL) (Invitrogen) in PBS was added and the covered plates were 
rotated on the Orbital Shaker at 50 rpm for 5 minutes at room temperature. The Hoechst 
was removed and the cells were washed three times with 2 mL of PBST for 5 minutes 
each on the Orbital Shaker at 50 rpm at room temperature. The coverslips were mounted 
on microscope slides using ProLong Gold Antifade Mountant (Invitrogen). The slides 
were left in the dark overnight to dry and were sealed the following day using nail polish. 





2.7 Cell Lysis 
FH-B and FH-B BioLSF cells were grown on 10 cm tissue culture plates and 
harvested at 80-90% confluence. The media was removed and the cells were scraped off 
the plate using a cell lifter (Corning) into 5 mL of 1X PBS. The scraped cells were 
transferred to a 15 mL conical tube. The cells were spun down at 1200 rpm for 5 minutes 
at 4°C (Sorvall T 6000D centrifuge). The supernatant was discarded and the cells were 
re-suspended in 5 mL of 1X PBS and spun down as before. The supernatant was 
discarded and the cells were re-suspended in 100 µL of Radioimmunoprecipitation assay 
(RIPA) buffer (50 mM Tris-Cl, pH 8, 150 mM NaCl, 1% Triton-X-100, 0.5% sodium 
deoxycholate, 0.1% SDS) supplemented with EDTA-free protease inhibitor cocktail 
(1:200) (Abcam) and transferred to an Eppendorf tube. The cells were freeze-thawed 
three times using liquid nitrogen. In order to verify that the cells had lysed, 5 µL of lysate 
was loaded onto a hemocytometer and checked using a microscope. If intact cells still 
remained, the cells were freeze-thawed using liquid nitrogen until all the cells had lysed. 
The lysates were flash frozen using liquid nitrogen and stored at -80°C.  
2.8 Cell Fractionation 
FH-B and FH-B BioLSF cells were grown on 10 cm tissue culture plates and 
harvested at 80-90% confluence. The media was removed and the cells were scraped off 
the plate using a cell lifter (Corning) into 5 mL of 1X PBS. The scraped cells were 
transferred to a 15 mL conical tube. The cells were spun down at 1200 rpm for 5 minutes 
at 4°C (Sorvall T 6000D centrifuge). The supernatant was discarded and the cells were 
re-suspended in 5 mL of 1X PBS and spun down as before. The supernatant was 
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discarded and the cells were re-suspended in 300 µL of Nuclei Isolation Buffer (5 mM 
PIPES, pH 8.1, 85 mM KCl, 0.5% Nonidet P40) and transferred to an Eppendorf tube. 
The cells were left on ice for 10 minutes. In order to verify that the cell membrane had 
lysed leaving intact nuclei, 5 µL of lysate was loaded onto a hemocytometer and checked 
using a microscope. The nuclei were spun down at 720xg for 5 min at 4°C using an 
Eppendorf 5417C microfuge. The supernatant (cytoplasmic fraction) was transferred to a 
new Eppendorf tube and kept on ice. The nuclei pellet was resuspended in 1 mL of 1X 
PBS and spun down at 1000xg for 30 seconds at room temperature using an Eppendorf 
5417C microfuge. The supernatant was discarded and the pellet was resuspended in 100 
µL of RIPA buffer (50 mM Tris-Cl, pH 8, 150 mM NaCl, 1% Triton-X-100, 0.5% 
sodium deoxycholate, 0.1% SDS) supplemented with EDTA-free protease inhibitor 
cocktail (1:200) (Abcam) (100 mM AEBSF hydrochloride, 0.08 mM aprotinin, 5 mM 
bestatin, 1.5 mM E-64, 2 mM leupeptin hemisulfate, 1 mM pepstatin A) by pipetting up 
and down 20 times and vortexing for 10 seconds to lyse the nuclei. The nuclear lysate 
was then spun down at 20,000xg for 2 minutes at 4°C. The supernatant (nuclear lysate) 
was transferred to a new Eppendorf tube. All lysates were flash frozen using liquid 
nitrogen and stored at -80°C.  
2.9 Nuclei Fractionation 
FH-B and FH-B BioLSF cells were grown on 10 cm tissue culture plates and 
harvested at 80-90% confluence. The media was removed and the cells were washed with 
1X PBS. The cells were scraped off the plate using a cell lifter (Corning) into 5 mL of 1X 
PBS and transferred to a 15 mL conical tube. The cells were centrifuged at 1200 rpm for 
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5 minutes at 4°C using the Sorvall T 6000D centrifuge. The supernatant was discarded 
and the cells were re-suspended in 5 mL of 1X PBS and spun down as before. The 
supernatant was discarded and the cells were re-suspended in 300 µL of Nuclei Isolation 
Buffer (5 mM PIPES, pH 8.1, 85 mM KCl, 0.5% Nonidet P40) and transferred to an 
Eppendorf tube. The cells were left on ice for 10 minutes. In order to verify that the cell 
membrane had lysed leaving intact nuclei, 5 µL of lysate was loaded onto a 
hemocytometer and checked using a microscope. The nuclei were spun down at 720xg 
for 5 min at 4°C in an Eppendorf 5417C microfuge. The supernatant (cytoplasmic 
fraction) was transferred to a new Eppendorf tube and kept on ice. The nuclear pellet was 
resuspended in 1 mL of 1X PBS and spun down at 720xg for 5 min at 4°C in an 
Eppendorf 5417C microfuge. The supernatant was discarded and the pellet was 
resuspended in 300 µL of Buffer B (3 mM EDTA, 0.2 mM EGTA) supplemented with 1 
mM DTT and protease inhibitor cocktail (1:200), and left on ice for 1 hour (Méndez & 
Stillman, 2000). The lysate was centrifuged at 1700xg for 5 min at 4°C in an Eppendorf 
5417C microfuge. The supernatant (soluble nuclear fraction) was transferred to a new 
Eppendorf tube. The pellet (insoluble nuclear fraction) was resuspended in 500 µL of 
Buffer B and sonicated using the Fisher Scientific Sonic Dismembrator Model 100 at 1 
watt power for 5 seconds. All lysates were flash frozen using liquid nitrogen and stored at 
-80°C. 
2.10 Immunoblotting 
The fractionated cellular lysates were electrophoresed through a 4% 
polyacrylamide stacking gel (0.1 M Tris-Cl, pH 6.8, 0.1% SDS) followed by a 7.5% or 
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15% separating gel (0.4 M Tris-Cl, pH 8.8, 0.1% SDS) in a 1X Tris-Glycine buffer (25 
mM Tris base, 0.2 M glycine) with 0.1% sodium dodecyl sulfate (SDS) at 0.02 amps 
through the stacking gel and 0.03 amps through the separating gel. The gel was then 
equilibrated in transfer buffer (1X Tris-Glycine buffer, 30% methanol) for 5 minutes. The 
proteins were then transferred from the separating gel to a polyvinylidene difluoride 
(PVDF) membrane by electroblotting at 4°C for 1 hour at 80 V in transfer buffer in a 
Mini Trans-Blot Cell (BioRad). The membrane was blocked in 10 mL of 5% BSA or 5% 
nonfat dry milk in TBST buffer (10 mM Tris-Cl, pH 8, 150 mM NaCl, 0.01% Tween20) 
for 1 hour at room temperature on a shaker. Primary antibody was then added directly to 
the membranes blocking solution and then left on a shaker at 4°C overnight. Information 
on the primary antibodies and dilutions used are provided in Table 2.1. The following 
day, the membrane was washed 3 times with TBST for 5 minutes each on the rotator. The 
membrane was then incubated in goat α-mouse horseradish peroxidase (HRP) (Thermo 
Fisher Scientific) (1:10,000) or goat α- rabbit HRP (Thermo Fisher Scientific) (1:10,000) 
secondary antibody in 10 mL of either 5% BSA or 5% nonfat dry milk in TBST (based 
on blocking solution used) for 1 hour on the rotator at room temperature. The membrane 
was washed 3 times with TBST for 5 minutes each on the rotator. The HRP on the 
secondary antibody was activated by incubating the membrane in either 10 mL of Pierce 
Enhanced Chemiluminescence (ECL) Western Blotting Substrate or EMD Millipore 
Immobilon Western Chemiluminescent HRP Substrate for 5 minutes at room temperature 
on the shaker.  The membrane was then exposed to BluLite Autoradiography Film (MTC 
Bio). The film was scanned using the CanoScanLiDE 700F scanner. Using the Fiji 
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software program, a box was drawn around each band and a blank area of the film 
(background signal) to quantify the intensity of the pixels within the box and a plot of 
intensity values was generated. The area under the peak, correlating to the intensity of the 
band, was quantified and the background signal was subtracted from the band signal.   
2.11 Streptavidin Blotting 
Sodium-dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) steps 
were done as indicated above. The membrane was blocked in 10 mL of 5% nonfat dry 
milk in TBST on a shaker at 4°C overnight. The following day, the membrane was 
washed 4 times with TBST for 15 minutes each on the shaker. The membrane was 
incubated in streptavidin HRP protein (1:15,000) in 5% nonfat milk in TBST for 1 hour 
at room temperature on the shaker. The membrane was washed as above. Activation of 
HRP and exposure was performed as above.  
2.12 Protein-Protein Interaction Assays 
FH-B and FH-B BioLSF cells were seeded in three 10 cm plates or one 15 cm 
plate and grown to 80-90% confluency. The cells were crosslinked by adding 16% 
methanol-free formaldehyde (final concentration of 1%) (Thermo Scientific Pierce, 
PI28908) to the media on the cells and gently agitating the plates so the formaldehyde 
was distributed evenly. The cells were left at room temperature in the tissue culture hood 
for 5 minutes. The reaction was quenched by adding 2.5 M glycine (final concentration of 
125 mM) and gently agitating the plate to evenly distribute the glycine. The cells were 
left at room temperature in the tissue culture hood for 5 minutes. The media, 
formaldehyde and glycine mixture on the cells was removed and transferred to a 50 mL 
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conical tube. The cells were scraped off the bottom of the plate using a cell lifter 
(Corning) into 5 mL of 1X PBS and transferred to the same 50 mL conical tube. The cells 
were centrifuged at 1200 rpm for 4 minutes at 4°C using the Sorvall T 6000D centrifuge. 
The supernatant was discarded and the pellet was resuspended in 5 mL of 1X PBS and 
centrifuged as before. The pellet was resuspended in 1 mL of chromatin 
immunoprecipitation (ChIP) buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 5 mM EDTA, 
1% Triton-X-100, 0.5% deoxycholate, 0.1% SDS) supplemented with protease inhibitor 
cocktail (1:200). The crosslinked cells were sonicated using Fisher Scientific Sonic 
Dismembrator Model 100 at 2 watts for two 30 second pulses with 10 second pauses 
between each pulse. The lysate was checked using a hemocytometer to verify that no 
intact cells or nuclei remained. If intact cells remained, the lysate was sonicated for an 
additional 30 seconds. A Bradford assay was performed using the BioRad Quick Start 
Bradford Protein Assay Kit 4 to determine the protein concentration of each lysate. 
Fifty µL of Millipore Dynabeads MyOne Streptavidin C1 beads were resuspended 
in 1XPBS. The beads were separated from the supernatant by leaving them on a magnetic 
rack for three minutes and then slowly removing the supernatant 200 µL at a time to 
prevent aspirating out any of the Dynabeads with the supernatant. The 1X PBS wash was 
done three times. The beads were blocked by adding 1 mL of 0.1% BSA in 1X PBS to 
the beads and pipetting up and down 10 times. The beads were separated and supernatant 
removed as described above. This was repeated 5 times. One fiftieth of the lysates were 
removed, before the lysates were added to the beads, to use as 2% inputs. Fifty µL of 
beads were added to 1 mL of lysate containing 2 mg of protein. The beads and lysate 
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were incubated on a nutator at 15 rpm overnight at 4°C. The following day, the non-
bound proteins were separated from the beads on the magnetic rack for 3 minutes and the 
supernatant containing the non-bound proteins was removed. The beads were 
sequentially incubated in 1 mL of each wash solution on a nutator at room temperature 
for 5 minutes. The sequence of washes was as follows: 2% SDS, 2% SDS, high salt 
buffer (50 mM HEPES, pH 7.5, 500 mM NaCl, 1 mM EDTA, 0.1% sodium 
deoxycholate, 1% Triton-X-100), LiCl buffer (10 mM Tris-HCl, pH 8.1, 250 mM LiCl, 1 
mM EDTA, 0.5% NP-40, 0.5% sodium deoxycholate), 1X PBS (He & Pu, 2011). After 
each wash, the beads were separated on the magnetic rack for 3 minutes and the 
supernatant was removed. All washes were supplemented with protease inhibitor cocktail 
(1:200). The beads were resuspended in 18 µL of 1X PBS. Six µL of 4X sample buffer 
(200 mM Tris-Cl pH 6.8, 8% SDS, 40% glycerol, 0.04% bromophenol blue, 5% β-
mercaptoethanol) were added to the beads in 1X PBS and incubated at 100°C for 30 
minutes. The beads were separated as before and the supernatant was transferred to a new 
Eppendorf tube. The samples were stored at -20°C.   
2,13 FQI1 Treatment 
FH-B BioLSF and FH-B cells were treated with 4 µM FQI1 (Schaus Lab) at a 
final concentration of 0.01% DMSO, 30 minutes prior to crosslinking for protein-protein 
interaction assays. DMSO was added to the non-treated cells at a final concentration of 






























80 kDa 5% BSA 7% 
α-α-tubulin Thermo Scientific 62204 Mouse 1:1,000 50 kDa 5% BSA 7% 
α-PARP Cell Signaling 9542 Rabbit 1:1,000 89 kDa 
5% Nonfat 
Milk 7% 
α-α-14-3-3 Upstate 06-511 Rabbit 1:2,000 28 kDa 5% BSA 12 or 15% 




Signaling D4B9 Rabbit 1:2,000 17 kDa 5% BSA 15% 
α-SP1 Santa Cruz 1C6X Mouse 1:1,000 90 kDa 5% Nonfat Milk 7% 
Streptavidin Abcam ab7403 - 1:10,000 80 kDa 5% Nonfat Milk 7% 
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CHAPTER 3: RESULTS  
3.1 Establishing a system to study LSF-protein interactions in FH-B cells 
To study biologically relevant protein interactions of LSF in FH-B cells, a 
biotin/streptavidin affinity system was used. This involved establishing a FH-B cell line 
that stably expresses LSF fused with a biotin carboxyl carrier protein (BCCP) domain, 
also known as a biotinyl domain. The biotinyl domain, found in all biotin-dependent 
carboxylases, contains a specific lysine residue within a highly conserved tetrapeptide 
sequence (Samols et al., 1988), to which biotin protein ligase (BPL) attaches a biotin 
group via an amide linkage between the carboxyl group of biotin and the ε amino group 
of the lysine residue (Reche & Perham, 1999). Though biotin-dependent enzymes are 
ubiquitously expressed, biotinylation by BPL is relatively rare and highly specific, 
making it ideal to tag recombinant proteins with the biotinyl domain to perform 
techniques that utilize the specific and high affinity bond between biotin and streptavidin 
(KD=10-15 M) (Chapman-Smith & Cronan, 1999; Cronan Jr., 1990). Streptavidin coated 
beads can stably bind biotinylated proteins under more stringent washing conditions than 
a traditional co-immunoprecipitation assay using an antibody, allowing for a better signal 
to noise ratio (Laitinen et al., 2007).  
Retroviral transduction was the chosen method to stably integrate the biotinyl-
LSF fusion (BioLSF) coding sequence into the FH-B cells because it is more efficient 
than transfections (Hwang & Gilboa, 1984). GP2-293 packaging cells, a HEK-293 based 
retroviral packaging cell line, stably integrated with viral packaging genes, gag and pol, 
were transfected with a plasmid encoding the viral VSV-G envelope protein and pBABE-
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puro-3XFLAGBioLSF-IRESEGFP, a retroviral vector containing the BioLSF cDNA 
downstream of the viral promoter/enhancer. The transfected GP2-293 cells produced 
retrovirus containing BioLSF encoding RNA, which was then used to infect the FH-B 
cells (Figure 3.1A). Puromycin resistance could not be used in this case as a selectable 
marker for transduced cells because the FH-B cell line is already puromycin-resistant, 
since it was initially established by using puromycin to select for hTERT expressing cells 
(Wege et al., 2003). Instead, EGFP expression from an IRES, downstream of the BioLSF 
coding sequences in the RNA, was used to sort out EGFP+ (transduced) cells from 
EGFP- (non-transduced) cells using fluorescence-activated cell sorting (FACS). The first 
FACS results showed that only 4.9% of the total population was transduced. Some non-
transduced and lowly expressing cells were kept with the transduced population in order 
to ensure that the transduced cells could be propagated at sufficient seeding density to 
maintain healthy growth. After propagation of the transduced cells, a second round of 
sorting isolated the transduced population, up to 27.1% of the cells (Figure 3.1B).  
3.2 BioLSF expression in transduced FH-B cells 
Immunofluorescence and immunoblots were used to verify that BioLSF was 
expressed in the transduced cells that had been sorted using EGFP expression. 
Immunofluorescence, done on the singly sorted transduced population, probing for the 
FLAG tag on BioLSF, confirmed FLAG-tagged BioLSF expression. However, FLAG-
immunofluorescence was observed mainly in the cytoplasm (Figure 3.2A). 
Immunoblotting of whole cell lysates with antibody against LSF determined whether 
additional FACS using EGFP expression enriched for BioLSF levels, as was expected, 
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and also allowed for comparison of BioLSF levels to endogenous LSF levels. The same 
membrane probed with streptavidin determined whether the biotinyl domain of BioLSF 
was biotinylated (Figure 3.2B). These results showed that overall BioLSF was expressed 
at higher levels than endogenous LSF and that the biotinyl domain of BioLSF was 
biotinylated. Surprisingly, there also appeared to be higher levels of endogenous LSF in 
the FH-B BioLSF cells compared to FH-B cells. Quantifying the endogenous LSF signal 
in the LSF blot exposed for 1 minute revealed that the FH-B BioLSF cells express 20 
times more endogenous LSF than FH-B cells. This suggests that LSF autoregulates itself 
by activating its own promoter since overexpressing LSF via BioLSF also increases 
endogenous LSF levels.  
  The immunofluorescence results indicated that the majority of BioLSF was 
localized in the cytoplasm, which has also been previously observed in the Hansen 
Laboratory when other tagged versions of LSF were overexpressed. In order to 
definitively demonstrate BioLSF expression in the nucleus, cellular lysates were 
fractionated into nuclear and cytoplasmic components.  
In order to analyze roughly equivalent amounts of protein in the immunoblots, the 
fact that the cytoplasm is larger than the nucleus in the FH-B cells was roughly accounted 
for by lysing the outer cell membrane using 300 µL of nuclei isolation buffer for the 
cytoplasmic fraction and lysing the nuclear membrane in 100 µL of RIPA buffer for the 
nuclear fraction, making the cytoplasmic fraction 3 times more dilute on a cellular basis 
than the nuclear fraction. Equal volumes of each fraction were loaded for SDS-PAGE. To 
verify clean biochemical fractionation, α-14-3-3 was used as a cytoplasmic marker 
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(Nomura et al., 2003) and PARP was used as a nuclear marker (Shi et al., 2009). 
Immunoblotting with antibody against FLAG showed that BioLSF was expressed in both 
the nucleus and cytoplasm (Figure 3.2C).  
The FLAG signal in the nuclear and cytoplasmic fractions appears to be roughly 
equal based on the immunoblot results, unlike the immunofluorescence results. However, 
equal volumes of the nuclear and cytoplasmic were loaded onto separate gels and 
transferred onto separate membranes in this experiment in order to detect BioLSF in the 
nuclear fraction. Furthermore, after treating both membranes with the same Pierce ECL 
Western Blotting Substrate, the membrane with the cytoplasmic fractions was exposed 
for 2 minutes while the membrane with the nuclear fractions was exposed for 5 minutes. 
When equal volumes of both fractions were loaded onto the same gel and transferred onto 
the same membrane, the BioLSF signal in the nuclear fraction was very difficult to 
detect, perhaps because the BioLSF signal in the cytoplasmic was very intense. 
Altogether this indicates that there is much less BioLSF in the nucleus compared to 
cytoplasm even though the levels appear to be the same on the immunoblots.  
3.3 BioLSF functions similarly to LSF 
LSF is primarily a transcription factor so it was important to know whether 
BioLSF could function as a transcription factor, in order to show that the biotinyl domain 
had not apparently altered the structure or function of LSF. The Hansen laboratory (Sarah 
Yunes and Gene Chin, personal communications) previously demonstrated that BioLSF 
is able to activate transcription using a LSF-dependent luciferase reporter assay (Figure 
3.3A). Nuclear fractionation experiments were performed to determine whether BioLSF 
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was binding chromatin associated genomic DNA in the FH-B BioLSF cells. The nuclear 
fractionation protocol for studying the binding of proteins to chromatin associated 
genomic DNA was adapted from a study analyzing the binding of hCdc6p, a protein that 
loads the stable pre-replicative complex onto origins of DNA replication, to chromatin 
(Méndez & Stillman, 2000). In this protocol, the nuclear lysate is further fractionated into 
a soluble and insoluble fraction, with both fractions being in the same volume of buffer. 
The insoluble fraction contained proteins stably bound to chromatin under these 
conditions while the soluble fraction contained unbound proteins that were either 
unbound or released during the protocol. SP1 was used as a soluble fraction marker and 
histone H3 was used as a insoluble fraction marker to verify clean biochemical 
fractionation (abcam, 2017). Immunoblots of the nuclear fractions indicated that BioLSF 
was stably bound to chromatin to the same degree as was endogenous LSF, suggesting 
that BioLSF can function similarly to endogenous LSF in the nucleus. (Figure 3.3B). 
Quantifying the BioLSF and endogenous LSF signals on the LSF blot revealed that there 
is double the amount of BioLSF bound to chromatin than endogenous LSF in the FH-B 
BioLSF cells.  
3.4 LSF-a-tubulin interactions in FH-B cells are diminished by FQI1 
A previous study using HEK-293 cells showed that LSF and a-tubulin directly 
interact with each other and that this interaction in cells is disrupted by FQI1 (Chin et al., 
manuscript submitted). To see whether this interaction also occurs in the FH-B cells, FH-
B BioLSF cell lysates were used for protein-protein interaction assays. Streptavidin 
coated beads were used to bind the biotin group attached to the biotinyl domain on 
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BioLSF in the cell lysates followed by analyzing the bound proteins by immunoblotting 
for LSF and a-tubulin. Results from two separate experiments showed that BioLSF 
interacts either directly or indirectly with a-tubulin in the FH-B BioLSF cells (Figure 
3.4A, lanes labelled “-“).  
Treating FH-B cells with FQI1 results in the cells losing their elongated shape and 
rounding up within 10 minutes of treatment (Pietro Rossi Scribani and Patrick Stoiber, 
personal communications). To probe whether this phenotype might be related to FQI1 
diminishing the LSF-a-tubulin interaction, FH-B BioLSF cells were treated with 4 µM 
FQI1 for 30 minutes, before being cross-linked and harvested for protein-protein 
interaction assays. The results from two separate experiments indicate that FQI1 
diminishes the LSF-a-tubulin interaction (Figure 3.4A, compare lanes labeled “+” with “-
“). Quantifying the ratio of bound a-tubulin to bound BioLSF and LSF showed that there 
are less LSF-a-tubulin interactions in FQI1-treated, as compared to non-treated, FH-B 
BioLSF cells (Figure 3.4B). Surprisingly, there was also less bound BioLSF and LSF in 
the FQI1 treated pulldowns compared to non-treated pulldowns, suggesting that FQI1 






Figure 3.1: Establishing a BioLSF expressing FH-B cell line. (A) A schematic of 
BioLSF with amino acid lengths provided for each domain, plasmids and workflow used 
to create a stable BioLSF expressing FH-B cell line. HEK-293 packaging cells were 
transfected with pCMV-VSV-G and pBabe-puro-3xFLAGBioLSF-IRESEGFP to make 
retrovirus carrying 3XFLAGBioLSF RNA. The retrovirus-containing supernatant was 
then added to the FH-B hTERT cells to infect them and for the 3XFLAGBioLSF coding 
sequence driven by the MMLV LTR to be stably integrated into the cellular genome. (B) 
FACS plots of number of events vs. EGFP expression for the first and second rounds of 
sorting the FH-B EGFP+ (transduced) from the FH-B EGFP- (non-transduced) cells 
using the using the Sony SH800S cell sorter with the percent of the total population 
collected for each round of sorting. The EGFP- population is represented in yellow-green 
for both sort 1 and 2. The EGFP+ population that was collected is represented in blue for 

















Figure 3.2. Verifying expression and localization of biotinylated BioLSF in FH-B 
cells. (A) 3XFLAGBioLSF expression was verified using immunofluorescence probing 
for the FLAG tag. Hoechst 3342, which stains DNA, indicates nuclei. Confocal images 
were acquired at 60x magnification. The scale bars are 200 µm. (B) FH-B BioLSF whole 
cell lysates prepared from cells sorted once or cells sorted twice, and blotted for both LSF 
and streptavidin showed higher BioLSF expression as compared to endogenous LSF 
expression and verified that the biotinyl domain of BioLSF is biotinylated respectively. A 
1 minute and 5 minute exposure of the LSF blot were included to better compare the 
relative levels of BioLSF to endogenous LSF. β-actin was used as a loading control. 
Parental FH-B whole cell lysates were used as a negative control. (C) Immunoblots of the 
nuclear and cytoplasmic fractions of FH-B BioLSF cells verified 3XFLAGBioLSF 
expression in both the nuclear and cytoplasmic fractions. PARP and α-14-3-3 were used 
as nuclear and cytoplasmic fraction loading controls respectively, and to verify clean 



















Figure 3.3. BioLSF is active and binds chromatin. (A) A plot of LSF-dependent dual 
luciferase reporter activity for each indicated construct transfected into HepG3 cells 
demonstrated that BioLSF can activate transcription. (Data obtained from Sarah Yunes 
and Deena Qadir) (B) Immunoblots of the insoluble (I) and soluble (S) nuclear fractions 
of FH-B and FH-B BioLSF blotted for LSF indicated that BioLSF is stably bound to 
chromatin. SP1 and histone H3 and were used as soluble and insoluble fraction loading 
controls respectively, and to verify clean biochemical fractionation. The bands in the 














Figure 3.4. LSF-α-tubulin interaction in FH-B cells is diminished by FQI1.  (A) 
Immunoblots of two protein-protein interaction assays show α-tubulin binding with 
BioLSF and endogenous LSF, with less α-tubulin bound in FQI1-treated cellular lysates 
compared to non-treated cellular lysates. Less BioLSF and endogenous LSF is also seen 
bound in FQI1-treated cellular lysates compared to non-treated cellular lysates suggesting 
that FQI1 also disrupts BioLSF-BioLSF and BioLSF-LSF interactions. (B) Plot of the 
ratio of α-tubulin to BioLSF and LSF signal in the streptavidin beads-eluted samples for 
FQI1-treated and non-treated lysates quantified from the 2 protein-protein interaction 




CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS 
 LSF has been well characterized as an oncogene in HCC, however not much is 
known about how it normally functions in hepatocytes. A biotin/streptavidin affinity 
system was first established in FH-B cells to create a tool that could be used to more 
efficiently study LSF functions. Immunofluorescence demonstrated that 
3XFLAGBioLSF was primarily expressed in the cytoplasm (Figure 3.2A). Keeping in 
mind the experimental techniques used for the cell fractionation and following 
immunoblots, further characterization showed that BioLSF was expressed much less in 
the nucleus as compared to the cytoplasm (Figure 3.2C). Though BioLSF levels appear to 
be equal in the nucleus and cytoplasm in the immunoblots of the fractionated cells 
(Figure 3.2C), the experimental technique used to fractionate the cells and for the 
immunoblots in this case make it so the immunoblots should not be taken at face value 
and still indicate that BioLSF is being expressed much less in the nucleus compared to 
the cytoplasm, as was seen with immunofluorescence.  
Overall, these results suggest that there is a highly regulated mechanism in FH-B 
cells that limits the amount of LSF localized to the nucleus. This is expected as LSF is a 
transcription factor and high levels of LSF in the nucleus would likely alter effects of 
LSF as a transcriptional regulator. Moreover, BioLSF is able to bind chromatin further 
strongly suggesting that the LSF structure has not been evidently altered by the biotinyl-
domain (Figure 3.3B).  
Recent studies in the Hansen Laboratory have shown that treating FH-B cells with 
FQI1 causes a rapid phenotype where the cells contract and lose their normal elongated 
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shape within 10 minutes (Pietro Scribani Rossi and Patrick Stoiber, personal 
communications). The unexpected speed at which this phenotype occurred suggested a 
non-transcriptional process being disrupted by FQI1. Furthermore, a separate previous 
study showed that LSF interacts with α-tubulin in HEK-203 cells and that this interaction 
is diminished by FQI1, demonstrating that LSF has functions beyond being a 
transcriptional regulator (Chin et al., manuscript submitted). It was hypothesized that the 
LSF-α-tubulin interaction also occurs in the FH-B cells and that FQI1 diminishes this 
interaction causing the cells to rapidly contract. Protein-protein interaction assays done 
using the biotin/streptavidin affinity system demonstrated that the LSF-α-tubulin 
interaction occurs in FH-B BioLSF cells and is apparently diminished by a 30-minute 
treatment with FQI1 (Figure 3.4A and B). While this may contribute to the phenotype 
seen, further studies need to be done to show whether α-tubulin alone causes this 
phenotype or more likely, whether there are other LSF-protein interactions and processes 
being disrupted that altogether contribute to the FH-B cells rapidly contracting. Previous 
studies in the Hansen laboratory showed that LSF can directly bind a-tubulin (Chin, et al, 
manuscript submitted). It would be important to determine if, in this instance, the LSF-α-
tubulin interaction is direct or indirect. To further probe whether and why the LSF-α-
tubulin interaction is important for stabilization of the microtubule cytoskeleton, the same 
experiment should be repeated with nocodazole, a microtubule-depolymerizing drug, to 
see if the LSF-α-tubulin interaction is also disrupted when microtubules depolymerize. If 
so, it would indicate that LSF can only interact with polymerized tubulin and that the 
LSF-α-tubulin interaction may be important for microtubule polymerization. Knowing 
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that FQI1 disrupts the microtubule cytoskeleton via inhibition of LSF makes it a 
promising therapeutic to treat HCC since studies have shown that compounds that target 
and disrupt microtubules are among the best types of cancer chemotherapeutics drugs 





A.1 BioLSF expression in QGY-7703 and NIH-3T3 cells 
Two additional cell lines stably expressing BioLSF were also established: QGY-
7703, a highly aggressive HCC cell line, and NIH-3T3 mouse fibroblasts. 
Immunofluorescence and immunoblots verified that 3XFLAGBioLSF was expressed and 
localized primarily in the cytoplasm for both QGY-7703 BioLSF cells and NIH-3T3 
BioLSF cells (Figure A1A and A1B). The QGY-7703 BioLSF cells overall expressed 
low levels of BioLSF as compared to FH-B BioLSF and NIH-3T3 BioLSF cells. This is 
perhaps because endogenous LSF is overexpressed in QGY-7703 cells, unlike FH-B and 
NIH-3T3 cells, making it so QGY-7703 cells do not have the capacity to express high 
levels of BioLSF.  
Cell fractionation and immunoblots verified that BioLSF was present in the 
nucleus of the QGY-7703 BioLSF and NIH-3T3 BioLSF cells (Figure A2A). In order to 
analyze roughly equivalent amounts of protein in the immunoblots, the fact that the 
cytoplasm is larger than the nucleus in the QGY-7703 and NIH-3T3 cells was roughly 
accounted for by lysing the outer cell membrane using 300 µL of nuclei isolation buffer 
for the cytoplasmic fraction and lysing the nuclear membrane in 100 µL of RIPA buffer 
for the nuclear fraction, making the cytoplasmic fraction 3 times more dilute on a cellular 
basis than the nuclear fraction. Equal volumes of each fraction were loaded for SDS-
PAGE. To verify clean biochemical fractionation, α-14-3-3 was used as a cytoplasmic 
marker (Nomura et al., 2003) and PARP was used as a nuclear marker (Shi et al., 2009). 
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The FLAG signal in the nuclear and cytoplasmic fractions of each cell line appear 
to be roughly equal based on the immunoblot results, unlike the immunofluorescence 
results. However, equal volumes of the nuclear and cytoplasmic were loaded onto 
separate gels and transferred into separate membranes in this experiment in order to 
detect BioLSF in the nuclear fraction. Furthermore, after treating both membranes with 
the same ECL, the membrane with the cytoplasmic fractions was exposed for 2 minutes 
while the membrane with the nuclear fractions was exposed for 5 minutes. When equal 
volumes of both fractions were loaded onto the same gel and transferred onto the same 
membrane, the BioLSF signal in the nuclear fraction was very difficult to detect, perhaps 
because the BioLSF signal in the cytoplasmic was very intense. Altogether this indicates 
that there is much less BioLSF in the nucleus compared to cytoplasm even though the 
levels appear to be the same on the immunoblots.  
A.2 Cell Cycle Analysis of FH-B BioLSF Cells 
To further probe whether BioLSF can function like LSF, LSF was knocked down 
using siRNA only targeting endogenous LSF, followed by cell cycle analysis to see if the 
previously observed S-phase depletion phenotype observed when LSF is knocked down 
in FH-B cells is also seen when LSF is knocked down in FH-B BioLSF cells or if 
BioLSF is able to rescue this defect. FH-B and FH-B BioLSF cells were treated with LSF 
siRNA or Luc siRNA (control) for two days, and then harvested and prepared for either 
immunoblotting or cell cycle analysis by flow cytometry of propidium iodide-stained 
cellular DNA. The immunoblot probing for LSF showed that LSF was knocked down in 
LSF siRNA-treated cells, as compared to the control siRNA-treated and untreated cells. 
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Although there appears to be lower levels of LSF in both siRNA-treated cell parental FH-
B cells compared to the untreated cells, the actin levels indicate that less amounts of 
protein were loaded for those siRNA-treated samples compared to the intreated sample. 
There still is a faint LSF signal for the control siRNA-treated FH-B parental cells that is 
absent in the LSF siRNA-treated cells (Figure A3A).  
The cell cycle profile was then analyzed using flow cytometry. In this single 
experiment, a slight depletion in G2/M cells and increase in G1/S cells was seen in 
untreated FH-B BioLSF cells as compared to untreated FH-B cells. In addition, a 
potentially less severe S-phase depletion was seen in FH-B BioLSF LSF siRNA-treated 
cells as compared to the S-phase depletion seen in FH-B LSF siRNA-treated cells (Figure 
A3B). These results need to be repeated and extended, but may indicate that BioLSF 
partially rescues LSF function in regulating the cell cycle.  
A.3 Materials and Methods  
A.3.1 Retroviral Infection and FACS of QGY-7703 cells 
Retroviral infection and FACS of the QGY-7703 cells were done using the same 
methodology as was done for the FH-B cells except that QGY-7703 parental cells were 
used as a negative control to set the background signal threshold. 2% of the total 
population was collected during sort 1 and 43% of the total population was collected 
during sort 2 
A.3.2 Retroviral Infection and FACS of NIH-3T3 
 Retroviral infection of the NIH-3T3 cells was done using the same methodology 
as was done for the FH-B cells. The infected NIH-3T3 cells were treated with puromycin 
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at a final concentration of 2 µg/mL every three days over a 9-day period to initially select 
for the transduced cells. FACS was then done once using the same methodology as was 
done for the FH-B cells. 56% of the total cell population was collected and the sorted 
cells were maintained in puromycin at a final concentration of 2 µg/mL.  
A.3.3 Cell Lysis 
QGY-7703 and NIH-3T3 cell lysis was overall performed using the same 
methodology as was done with FH-B cells except that the cells were pipetted up and 
down and vortexed to lyse instead of flash-freezing using liquid nitrogen.  
A.3.4 siRNA Transfection 
FH-B and FH-B BioLSF (1x105) cells were seeded in 6-well plates the day before 
transfection. The following day, the cells were transfected using RNAimax (Life 
Technologies). In a tissue culture hood, the RNAimax was diluted 1:25 using Opti-MEM 
(Gibco). The solution was gently mixed by swirling and incubated at room temperature 
for 5 minutes. Either 0.5 µL of the LSF siRNA (Alnylam Pharmaceuticals) or control Luc 
siRNA (Alnylam Pharmaceuticals) targeting luciferase, which is not expressed in the 
mammalian cells, were added to 249.5 µL of Opti-MEM in an Eppendorf tubes. The 
siRNA/Opti-MEM mixtures were added to the RNAimax mixtures and gently swirled to 
mix. The solution was left at room temperature for 10 minutes. The media on the cells 
was removed and replaced with 1 mL of fresh media. 500 µL of the transfection solution 
was added to the 1 mL of media on the cells. The cells were incubated in a 5% CO2 




A.3.5 Propidium Iodide Staining and Flow Cytometry 
The media from the cells to be harvested was transferred to a 15 mL conical tube. 
The cells were washed with 2 mL of 1X PBS. One mL of 0.05% trypsin was added and 
incubated at 37°C in 5% CO2 atmosphere for 5 minutes. The trypsin was quenched using 
the media that was removed from the cells and the entire solution with cells was 
transferred back to the 15 mL conical tube. The cells were spun down at 1500 rpm at 4° 
for 5 minutes using the Sorvall T 6000D centrifuge. The supernatant was removed and 
the pellet was slowly re-suspended in 150 µL of 1X PBS. The suspended cells were 
added slowly in a drop-by-drop fashion to 350 µL of ice-cold ethanol (stored at -80°C). 
The cells were left at 4°C overnight to fix. The following day, the cells were spun down 
at 1200 rpm for 5 min in an Eppendorf 5417C microfuge. The supernatant was discarded 
and the cells were slowly re-suspended in 500 µL of cold 1XPBS. The cells were spun 
down as before. The supernatant was removed and the cells were resuspended in 1 mL of 
propidium iodide (final concentration 50 µg/mL) supplemented with RNase (final 
concentration 10 µg/mL). The samples were left at room temperature in the dark for 45 
minutes. The samples were filtered and transferred to FACS tubes. The samples were 







Figure A1. Verifying expression of biotinylated BioLSF in transduced QGY-7703 
and NIH-3T3 cells. (A) 3XFLAGBioLSF expression was verified using 
immunofluorescence probing for the FLAG tag. Hoechst 3342, which stains DNA, 
indicates nuclei. Confocal images were acquired at 60x magnification. The scale bars are 
200 µm. (B) QGY-7703 BioLSF whole cell lysates prepared from cells sorted once or 
cells sorted twice, and blotted for both LSF and streptavidin showed BioLSF expression 
slightly enriched after the second round of sorting and verified that the biotinyl domain of 
BioLSF is biotinylated respectively. NIH-3T3 whole lysates prepared from cells sorted 
once and blotted for both LSF and streptavidin showed BioLSF expression and verified 
that the biotinyl domain of BioLSF is biotinylated respectively.  β-actin was used as a 
loading control. Parental QGY-7703 and NIH-3T3 whole cell lysates were used as 














Figure A2. 3XFLAGBioLSF is expressed in the nucleus and cytoplasm of QGY-7703 
BioLSF and NIH-3T3 BioLSF cells. (A) Immunoblots of the nuclear and cytoplasmic 
fractions of QGY-7703 BioLSF and NIH-3T3 BioLSF cells verified 3XFLAGBioLSF 
expression in both the nuclear and cytoplasmic fractions. PARP and α-14-3-3 were used 
as nuclear and cytoplasmic fraction loading controls respectively, and to verify clean 












Figure A3. Cell cycle analysis of LSF siRNA treated FH-B vs. FH-B BioLSF cells. 
(A) Immunoblot of LSF siRNA transfected FH-B and FH-BioLSF cells blotted for LSF 
verified that endogenous LSF levels are lower in both cell lines after treating with LSF 
siRNA for two days. Luc siRNA was used as a control for any differences due to the 
transfection and untreated cells were used as a negative control. β-actin was used as a 
loading control. (B) Flow cytometry histograms of propidium iodide stained FH-B cells 
and FH-B BioLSF cells treated with LSF siRNA or Luc siRNA and untreated cells, along 
with the percent of cells in each stage of the cell cycle suggest that there are minor 
differences in the cell cycle profile of LSF siRNA versus untreated FH-B BioLSF cells. 
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